MTOR inhibitor-based combination therapies for pancreatic cancer

BACKGROUND: Although the mechanistic target of rapamycin (MTOR) kinase, included in the mTORC1 and mTORC2 signalling hubs, has been demonstrated to be active in a significant fraction of patients with pancreatic ductal adenocarcinoma (PDAC), the value of the kinase as a therapeutic target needs furt...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Br J Cancer
Hoofdauteurs: Hassan, Zonera, Schneeweis, Christian, Wirth, Matthias, Veltkamp, Christian, Dantes, Zahra, Feuerecker, Benedikt, Ceyhan, Güralp O, Knauer, Shirley K, Weichert, Wilko, Schmid, Roland M, Stauber, Roland, Arlt, Alexander, Krämer, Oliver H, Rad, Roland, Reichert, Maximilian, Saur, Dieter, Schneider, Günter
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Nature Publishing Group 2018
Onderwerpen:
Translational Therapeutics
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5808033/
https://ncbi.nlm.nih.gov/pubmed/29384525
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2017.421
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items